Shimo Arata, Tanikawa Chizu, Nishidate Toshihiko, Lin Meng-Lay, Matsuda Koichi, Park Jae-Hyun, Ueki Tomomi, Ohta Tomohiko, Hirata Koichi, Fukuda Mamoru, Nakamura Yusuke, Katagiri Toyomasa
Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-Ku, Tokyo 108-8639, Japan.
Cancer Sci. 2008 Jan;99(1):62-70. doi: 10.1111/j.1349-7006.2007.00635.x. Epub 2007 Oct 18.
To elucidate the molecular mechanisms of mammary carcinogenesis and discover novel therapeutic targets for breast cancer, we previously carried out genome-wide expression profile analysis of 81 breast cancer cases by means of cDNA microarray coupled with laser microbeam microdissection of cancer cells. Among the dozens of transactivated genes, in the present study we focused on the functional significance of kinesin family member 2C (KIF2C)/mitotic centromere-associated kinesin (MCAK) in the growth of breast cancer cells. Northern blot and immunohistochemical analyses confirmed KIF2C/MCAK overexpression in breast cancer cells, and showed that it is expressed at undetectable levels in normal human tissues except the testis, suggesting KIF2C/MCAK to be a cancer-testis antigen. Western blot analysis using breast cancer cell lines revealed a significant increase in the endogenous KIF2C/MCAK protein level and its phosphorylation in G(2)/M phase. Treatment of breast cancer cells with small interfering RNA against KIF2C/MCAK effectively suppressed KIF2C/MCAK expression and inhibited the growth of the breast cancer cell lines T47D and HBC5. In addition, we found that KIF2C/MCAK expression was significantly suppressed by ectopic introduction of p53. These findings suggest that overexpression of KIF2C/MCAK might be involved in breast carcinogenesis and is a promising therapeutic target for breast cancers.
为阐明乳腺癌发生的分子机制并发现新的乳腺癌治疗靶点,我们之前通过cDNA微阵列结合癌细胞激光微束显微切割技术,对81例乳腺癌病例进行了全基因组表达谱分析。在众多被激活的基因中,在本研究中我们重点关注驱动蛋白家族成员2C(KIF2C)/有丝分裂着丝粒相关驱动蛋白(MCAK)在乳腺癌细胞生长中的功能意义。Northern印迹和免疫组化分析证实了KIF2C/MCAK在乳腺癌细胞中的过表达,并表明除睾丸外,其在正常人体组织中的表达水平无法检测到,提示KIF2C/MCAK是一种癌-睾丸抗原。使用乳腺癌细胞系进行的Western印迹分析显示,内源性KIF2C/MCAK蛋白水平及其在G(2)/M期的磷酸化显著增加。用针对KIF2C/MCAK的小干扰RNA处理乳腺癌细胞可有效抑制KIF2C/MCAK表达,并抑制乳腺癌细胞系T47D和HBC5的生长。此外,我们发现通过异位导入p53可显著抑制KIF2C/MCAK的表达。这些发现提示,KIF2C/MCAK的过表达可能参与乳腺癌的发生,并且是乳腺癌有前景的治疗靶点。